Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
132 USD | +0.15% | +6.74% | +21.03% |
Mar. 28 | Robert Davis, Merck CEO: Another obesity drug? | MT |
Mar. 28 | Merck: new indication approved for Keytruda in Europe | CF |
- Stock
- Equities
- Stock Merck & Co., Inc. - Nyse
- News Merck & Co., Inc.